David S. Yee

David S. Yee

Auto-generated profile, based on publicly available information

David S. Yee

Urology Service, Department of Surgery, Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
DYDavid S. Yee
David S. Yee
YTYaxiong Tang
Yaxiong Tang
XLXuesen Li
Xuesen Li
ZLZhongbo Liu
Zhongbo Liu
YGYi Guo
Yi Guo
XZXiaolin Zi
Xiaolin Zi
Background: Aberrations in the Wnt pathway have been reported to be involved in the metastasis of prostate cancer (PCa) to bone. We investigated the effect and underlying mechanism of a naturally-occurring Wnt inhibitor, WIF1, on the growth and cellular invasiveness of a bone metastatic PCa cell line, PC3. Results: The WIF1 gene promoter was hypermethylated and its expression down-regulated in the majority (7 of 8) of PCa cell lines. Restoration of WIF1 expression in PC-3 cells resulted in a decreased cell motility and invasiveness via up-regulation of epithelial markers (E-cadherin, Keratin-8 and-18), down-regulation of mesenchymal markers (N-cadherin, Fibronectin and Vimentin) and decreased activity of MMP-2 and -9. PC3 cells transfected with WIF1 consistently demonstrated reduced expression of Epithelial-to-Mesenchymal Transition (EMT) transcription factors, Slug and Twist, and a change in morphology from mesenchymal to epithelial. Moreover, WIF1 expression significantly reduced tumor growth by approximately 63% in a xenograft mouse model. This was accompanied by an increased expression of E-cadherin and Keratin-18 and a decreased expression of vimentin in tumor tissues. Conclusion: These data suggest that WIF1 regulates tumor invasion through EMT process and thus, may play an important role in controlling metastatic disease in PCa patients. Blocking Wnt signaling in PCa by WIF1 may represent a novel strategy in the future to reduce metastatic disease burden in PCa patients.

1 May 2010 in Urology
Verified
Journal Article
Closed access
DYDavid S. Yee
David S. Yee
DKDarren J. Katz
Darren J. Katz
GGGuilherme Godoy
Guilherme Godoy
LNLUCAS NOGUEIRA
LUCAS NOGUEIRA
KCKian Tai Chong
Kian Tai Chong
JCJonathan Coleman
Jonathan Coleman

2 November 2010 in BJU International
Verified
Journal Article
Open access
PDF file
DYDavid S. Yee
David S. Yee
SSShahrokh F. Shariat
Shahrokh F. Shariat
WLWilliam T. Lowrance
William T. Lowrance
AMAlexandra C. Maschino
Alexandra C. Maschino
CSCaroline J. Savage
Caroline J. Savage
JEJames A. Eastham
James A. Eastham
Study Type – Prognosis (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? The reported incidence of lymphovascular invasion (LVI) in radical prostatectomy specimens ranges from 5% to 53%. Although LVI has a strong and significant association with adverse clinicopathologic features, it has almost uniformly not been found to be a predictor of biochemical recurrence (BR) on multivariate analysis. This study confirms that LVI is associated with features of aggressive disease and is an independent predictor of BCR. Given that LVI may play a role in the metastatic process, it may be useful in clinical decision‐making regarding adjuvant therapy for patients treated with RP. OBJECTIVES: To determine whether lymphovascular invasion (LVI) in radical prostatectomy (RP) specimens has prognostic significance. The study examined whether LVI is associated with clinicopathological characteristics and biochemical recurrence (BCR). PATIENTS AND METHODS: LVI was evaluated based on routine pathology reports on 1298 patients treated with RP for clinically localized prostate cancer between 2004 and 2007. LVI was defined as the unequivocal presence of tumour cells within an endothelium‐lined space. The association between LVI and clinicopathological features was assessed with univariate logistic regression. Cox regression was used to test the association between LVI and BCR. RESULTS: LVI was identified in 10% (129/1298) of patients. The presence of LVI increased with advancing pathological stage: 2% (20/820) in pT2N0 patients, 16% (58/363) in pT3N0 patients and 17% (2/12) in pT4N0 patients; and was highest in patients with pN1 disease (52%; 49/94). Univariate analysis showed an association between LVI and higher preoperative prostate‐specific antigen levels and Gleason scores, and a greater likelihood of extraprostatic extension, seminal vesicle invasion, lymph node metastasis and positive surgical margins (all P < 0.001). With a median follow‐up of 27 months, LVI was significantly associated with an increased risk of BCR after RP on univariate ( P < 0.001) and multivariate analysis (hazard ratio, 1.77; 95% confidence interval, 1.11–2.82; P = 0.017). As a result of the relatively short follow‐up, the predictive accuracy of the standard clinicopathological features was high (concordance index, 0.880), and inclusion of LVI only marginally improved the predictive accuracy (0.884). CONCLUSIONS: Although associated with features of aggressive disease and BCR, LVI added minimally to established predictors on short follow‐up. Further study of cohorts with longer follow‐up is warranted to help determine its prognostic significance.

30 April 2009 in Journal of Urology
Verified
Journal Article
Closed access
DYDavid S Yee
David S Yee
JEJames A Eastham
James A Eastham
WLWilliam T Lowrance
William T Lowrance
AMAlexandra C Maschino
Alexandra C Maschino
ACAngel M Cronin
Angel M Cronin
FRFarhang Rabbani
Farhang Rabbani